Chonluten peptide: the Glu-Asp-Gly bioregulator, what has been studied and what has not

Chonluten, or the EDG peptide, is a three-amino-acid peptide: glutamic acid, aspartic acid and glycine. It belongs to the family of short synthetic peptides that the Khavinson group in St Petersburg calls bioregulators, which they designed after analysing peptide extracts from animal organs and then synthesising the shortest fragments they believed carried the activity. A 2022 review from the institute lists Chonluten (EDG) with the stated activities of gastroprotector and stress protector, and places it among 26 short peptides that the group regards as biologically active ^[1]. A 2022 paper with Italian collaborators describes the Chonluten tripeptide as derived from bronchial epithelial cells and as a synthetic bronchial bioregulator whose principal target is the respiratory system ^[2].

That double description, lung on the one hand and stomach on the other, is a feature of the literature rather than a contradiction we can resolve. Research suppliers sell chonluten as a lung and airway peptide, and the two peer-reviewed papers that mention it by name lean in different directions. The related tetrapeptide Ala-Asp-Glu-Leu, sold as bronchogen, is the one the institute has studied more thoroughly in bronchial epithelium ^[6].

Chonluten belongs with the other Khavinson tripeptides on this site: crystagen (Glu-Asp-Pro, immune), ovagen (Glu-Asp-Leu, kidney and liver), pinealon (Glu-Asp-Arg, brain), vesugen (Lys-Glu-Asp, blood vessels) and cartalax (Ala-Glu-Asp, cartilage). All share a glutamate-aspartate core and were studied in the same laboratories by the same methods, so what is true of the evidence for one is largely true of the others.

The St Petersburg programme began in the 1970s with extracts of animal organs, the best known being thymalin from calf thymus and epithalamin from calf pineal gland. In 2002 Khavinson and Morozov reported that 266 elderly people given thymalin, epithalamin or both for the first two to three years of a six-to-eight-year follow-up had fewer acute respiratory infections, less ischaemic heart disease, hypertension and osteoporosis, and lower mortality than a control group, with a 4.1-fold fall in mortality in the group treated with both preparations every year ^[9]. That study is the foundation of the group’s claim that peptide bioregulators are geroprotectors. It was not blinded, the control group is not described in the abstract, and it has never been replicated outside the group.

The synthetic short peptides came later. Khavinson and Malinin set out the reasoning in a 2002 review: in their model, peptides normalise the synthesis of tissue-specific proteins and regulate the genes responsible for cell proliferation and differentiation, and in doing so maintain physiological function and slow ageing ^[10]. Under that model the institute produced a dipeptide or tripeptide for almost every organ, each named for its target and sold as a supplement: chonluten for the lungs and stomach, vesugen for blood vessels, pinealon for the brain, cartalax for cartilage and so on. The synthetic peptides are called cytogens; the original extracts are called cytomaxes.

When reading claims about chonluten bioregulator products, three features of this literature matter. Almost every paper comes from one institute or its collaborators; many are in Russian in the institute’s own journal, Advances in Gerontology, with only an abstract in English; and the English-language papers are mostly in the Bulletin of Experimental Biology and Medicine, a translated Russian journal that is indexed in PubMed but does not amount to independent replication. None of this makes the findings wrong, but it means the evidence for chonluten has never been tested by anyone with no stake in the result.

The Khavinson group’s central hypothesis is that very short peptides enter cells, bind particular DNA sequences in gene promoters and change the expression of tissue-specific genes, which they propose is how a tripeptide could act on one organ rather than another. For chonluten specifically, a 2012 paper reported that the peptide the institute coded T-34 regulates the expression of messenger RNA for genes encoding antioxidant and anti-inflammatory proteins, and that it normalised synthesis of those proteins in the setting of gastric ulcer ^[4]. A companion paper from the same institute in the same year identifies T-34 as Glu-Asp-Gly ^[3].

How the peptide gets into cells is addressed by two modelling papers. A 2022 review proposed that di- and tripeptides are carried into cells by the PEPT family of peptide transporters and by the LAT1 and LAT2 amino acid transporters, and gave EDG one of the highest computed binding scores to LAT1 of any peptide in its table ^[1]. A 2023 docking study of 26 short peptides again found EDG among the most effective computed ligands of LAT1, LAT2 and PEPT1, and speculated that an antitumour effect of EDG and a few other peptides could come from inhibiting those transporters ^[5]. Both papers are computer models; neither measured transport of EDG into any cell.

The one mechanistic study with human cells found that chonluten inhibited TNF production by THP-1 monocytes exposed to bacterial lipopolysaccharide, an effect the authors linked to TNF tolerance, and that, like the other four Khavinson peptides tested, it reduced LPS-stimulated TNF and IL-6 expression in differentiated macrophages and reduced monocyte adhesion to activated endothelial cells ^[2]. Those are laboratory findings at chosen concentrations in a leukaemia-derived cell line.

Searches for chonluten benefits, and for chonluten lung effects in particular, are usually about lung health, asthma, COPD, breathing or recovery from respiratory infection. We found no study, in animals or people, of chonluten in any of those conditions. The peer-reviewed evidence base for the tripeptide consists of the following.

Cell culture: in 2012, Voicekhovskaya and colleagues added five tripeptides at the institute to organotypic skin cultures from young and old rats. All of them stimulated cell proliferation in skin from young rats except T-34, the Glu-Asp-Gly peptide, which had no such effect; in old rat skin only Lys-Glu-Asp produced a marked effect ^[3]. In 2022, chonluten was one of five peptides that modulated proliferation signalling and reduced inflammatory cytokine release in THP-1 monocytes and macrophages, and it was singled out for inhibiting TNF production by LPS-exposed monocytes ^[2].

Animals: the 2012 gene-expression paper describes T-34 in the context of experimental gastric ulcer, reporting that it normalised the synthesis of antioxidant and anti-inflammatory proteins by regulating their genes ^[4]. The abstract does not give the species, dose, route or number of animals, and we could not obtain the full text. The institute’s 2022 review labels EDG a gastroprotector and a stress protector, citing patents rather than trials ^[1].

Lung: the airway evidence the institute cites for its bronchial peptides comes from the tetrapeptide AEDL (bronchogen), not from chonluten. In cultured human bronchial epithelial cells, AEDL regulated the levels of Ki67, Mcl-1, p53, CD79 and NOS-3 proteins, changed expression of the differentiation genes NKX2-1, SCGB1A1, SCGB3A2, FOXA1 and FOXA2, and was shown by spectroscopy to interact with DNA ^[6]. A 2015 follow-up linked some of those expression changes to promoter methylation ^[7]. Neither paper tested EDG.

There is no evidence for chonluten in anti-ageing, athletic performance or immune support beyond the cell-culture cytokine findings, and the institute’s own 2013 review of the clinical results of its peptide preparations does not list chonluten among them ^[8].

We found no clinical trial, case series or case report of chonluten or Glu-Asp-Gly in people in PubMed, and none registered on ClinicalTrials.gov. The Khavinson group’s 2013 summary of its clinical work names thymalin, thymogen, vilon, epithalamin, prostatilen, cortexin and retinalamin, and does not mention chonluten ^[8]. Claims on supplier websites that chonluten has been used in patients with bronchitis, asthma or COPD are not supported by any paper we could find, and may derive from unpublished material or from the group’s work on other lung peptides.

This distinguishes chonluten from the two Khavinson preparations that do have human data: thymogen, a registered medicine in Russia with published clinical studies, and thymalin, the calf thymus extract from which it was derived. For a peptide with real trials in lung inflammation, see thymulin, which has animal asthma data and two 1980s double-blind trials in other conditions.

There are no data. No study has given chonluten to an animal or a person over time and measured a lung or other outcome, so there is no published onset or duration of effect. The THP-1 cytokine changes were measured within hours of adding the peptide to the culture dish ^[2], which says nothing about timing in a living organism.

No human dose exists because there are no human studies. In the THP-1 study, peptides were added to the culture medium at concentrations the authors describe as known to be effective on recipient cells in culture ^[2]; in the rat skin culture study the related tripeptides were used at 0.1, 1 and 10 ng/mL ^[3]. The 2012 gastric ulcer paper does not report a dose in its abstract ^[4]. Suppliers commonly sell chonluten as 20 mg vials of lyophilised powder or as capsules and quote protocols copied from other bioregulator products; those protocols have not been tested in any published study, and we do not recommend any dose. To convert vial contents to a concentration for laboratory use, see the chonluten calculator or the general peptide calculator.

The published work used chonluten only in cell culture ^{[2] [3]} and in an animal ulcer model whose route is not stated in the abstract ^[4]. Research suppliers sell it as a freeze-dried powder for reconstitution with bacteriostatic water and as oral capsules. There are no data on absorption of Glu-Asp-Gly by mouth or injection in people; the transporter papers argue that tripeptides could be absorbed through PEPT1 in the gut ^{[1] [5]}, which is a hypothesis from computer modelling.

There is no published safety information on chonluten in people. The cell studies did not report toxicity at the concentrations used ^{[2] [3]}, which says nothing about safety in a person. Two points deserve mention. First, the 2023 modelling paper raised the possibility that EDG inhibits the LAT1 and PEPT1 transporters ^[5]; LAT1 supplies amino acids to many tissues, and an inhibitor would not be a neutral substance if the model were right. Second, the tripeptide reduced inflammatory cytokine release in immune cells ^[2], and anything that suppresses immune signalling has potential downsides during infection. Neither point has been examined in an animal or a person.

Chonluten is not named on the WADA Prohibited List or on the FDA’s lists of bulk substances for compounding as far as we have seen. That reflects the absence of any regulatory review rather than a judgement about safety. For the rules on possession and sale, see our legal status overview.

Chonluten is not an approved medicine in any country we are aware of. In Russia the Khavinson institute’s synthetic tripeptides are marketed as dietary supplements or cosmetics rather than as registered drugs, in contrast to thymogen, which is a registered medicine ^[1]. Outside Russia, products sold as chonluten are unlicensed research chemicals labelled for laboratory use.

See the UK, US and Europe pages for what applies where you are, and our explainer on what research peptides are.

Chonluten is a small, highly water-soluble peptide supplied as a freeze-dried powder. It is generally stored refrigerated, dry and away from light, and reconstituted solutions are kept cold and used within a limited period. See how to store peptides.

A tripeptide is easy to synthesise, so purity should be high and the price low. A certificate of analysis for chonluten should show a mass close to 319 g/mol and purity by HPLC; because the molecule is so small, mass spectrometry alone cannot distinguish it from other peptides of the same composition, such as Glu-Gly-Asp. Learn how to read a peptide COA and what third-party testing does and does not tell you.

Compare chonluten prices across suppliers, including listings in the UK and US, and see our list of third-party tested suppliers. If a listing cites clinical studies of chonluten in lung disease, ask for the reference; we could not find one. Our guide to spotting a fake peptide supplier covers the other checks worth making.